Intranasal fluticasone propionate: Phase III data

The open-label, U.S. Phase III EXHANCE-12 trial in 223 patients with chronic rhinosinusitis with or without nasal polyps showed that twice-daily 372 ug OPN-375 for 52 weeks was well tolerated, with ep...